These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
79 related articles for article (PubMed ID: 4018872)
1. Comparison of proportions based on the same or paired subjects. Radhakrishna S; Jayabal P; Jayasri R; Nair NG Indian J Med Res; 1985 Apr; 81():422-7. PubMed ID: 4018872 [No Abstract] [Full Text] [Related]
2. Paired versus two-sample design for a clinical trial of treatments with dichotomous outcome: power considerations. Wacholder S; Weinberg CR Biometrics; 1982 Sep; 38(3):801-12. PubMed ID: 7171700 [TBL] [Abstract][Full Text] [Related]
3. Reporting cumulative proportion of subjects with an adverse event based on data from multiple studies. Chuang-Stein C; Beltangady M Pharm Stat; 2011; 10(1):3-7. PubMed ID: 20073040 [TBL] [Abstract][Full Text] [Related]
4. Historical controls, data banks, and randomized trials in clinical research: a review. Fleming TR Cancer Treat Rep; 1982 May; 66(5):1101-5. PubMed ID: 7083214 [No Abstract] [Full Text] [Related]
5. Strategy and alternate randomized designs in cancer clinical trials. Zelen M Cancer Treat Rep; 1982 May; 66(5):1095-100. PubMed ID: 7083213 [No Abstract] [Full Text] [Related]
7. Allocation of subjects in medical experiments. Weinstein MC N Engl J Med; 1974 Dec; 291(24):1278-85. PubMed ID: 4610387 [No Abstract] [Full Text] [Related]
8. Clinical trial designs based on sequential conditional probability ratio tests and reverse stochastic curtailing. Tan M; Xiong X; Kutner MH Biometrics; 1998 Jun; 54(2):682-95. PubMed ID: 9629648 [TBL] [Abstract][Full Text] [Related]
9. Regulatory perspectives on multiplicity in adaptive design clinical trials throughout a drug development program. Wang SJ; Hung HM; O'Neill R J Biopharm Stat; 2011 Jul; 21(4):846-59. PubMed ID: 21516573 [TBL] [Abstract][Full Text] [Related]
10. Sample size for testing and estimating the difference between two paired and unpaired proportions: a 'two-step' procedure combining power and the probability of obtaining a precise estimate. Cesana BM Stat Med; 2004 Aug; 23(15):2359-73. PubMed ID: 15273953 [TBL] [Abstract][Full Text] [Related]
11. The clinician as investigator: participating in clinical trials in the practice setting: Appendix 2: statistical concepts in study design and analysis. Lader EW; Cannon CP; Ohman EM; Newby LK; Sulmasy DP; Barst RJ; Fair JM; Flather M; Freedman JE; Frye RL; Hand MM; Jesse RL; Van de Werf F; Costa F; Circulation; 2004 Jun; 109(21):e305-7. PubMed ID: 15173053 [No Abstract] [Full Text] [Related]
12. The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial. Survey of 71 "negative" trials. Freiman JA; Chalmers TC; Smith H; Kuebler RR N Engl J Med; 1978 Sep; 299(13):690-4. PubMed ID: 355881 [TBL] [Abstract][Full Text] [Related]
14. The crossover experiment for clinical trials. Brown BW Biometrics; 1980 Mar; 36(1):69-79. PubMed ID: 7370374 [TBL] [Abstract][Full Text] [Related]
15. Design of clinical trials for treatment of opiate dependence: what is missing? Jain RB NIDA Res Monogr; 1992; 128():29-36; discussion 37-45. PubMed ID: 1436014 [No Abstract] [Full Text] [Related]